Mepolizumab reduces blood eosinophils with concomitant clinical improvement in some hypereosinophilic syndromes and eosinophilic asthma. Objectives: To investigate the efficacy and safety of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss). Methods: We conducted a Phase III, randomised, placebo-controlled, doubleblind, parallel group, multi-centre study (NCT02020889) in patients with EGPA and a history of relapsing or refractory disease on stable therapy with prednisolone/prednisone ≥7.5-≤50mg/day with or without additional immunosuppressive therapy for ≥4 weeks. Patients were randomised 1:1 to receive mepolizumab 300mg or placebo subcutaneously, in addition to standard of care, every 4 weeks for 52 weeks. After Week 4, glucocorticoid dose could be tapered, per physician judgment, according to a suggested standard of care protocol. 
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Hazard ratio (99% CI) for flare vs PBO+26 was 0.23 (0.09-0.61) for TCZ-QW and 0.42 (0.14-1.28) for TCZ-Q2W; vs PBO+52 it was 0.36 (0.13-1.00) for TCZ-QW and 0.67 (0.21-2.10) for TCZ-Q2W. TCZ exposure-efficacy analysis showed that most patients in the low exposure tertile had been treated with TCZ-Q2W (80%) whereas those with medium and high exposure primarily received TCZ-QW (84% and 98%, respectively). Kaplan-Meier analysis demonstrated that patients with higher exposure benefited from a longer time to flare (Figure) . Adverse events (AEs) were similar across groups. Serious AEs were reported in 15.0% TCZ-QW, 14.3% TCZ-Q2W, 22.0% PBO+26 and 25.5% PBO+52 patients; rates were similar between new-onset and relapsing patients.
Conclusions:
The compelling treatment effect of TCZ in GCA patients as measured by sustained remission to 52 weeks was consistent regardless of disease-onset status. Duration of relapse-free remission until flare was longer in patients with higher TCZ exposure, most notably in relapsing patients treated with TCZ-QW. 
